World Health Organization has granted prequalification to Artemether/lumefantrine, making it the first malaria treatment specifically formulated for newborns and infants. This landmark approval addresses a critical gap in malaria care, as young infants have previously been treated using formulations intended for older children, increasing the risk of dosing inaccuracies, adverse effects, and toxicity. WHO stated that prequalification confirms the medicine meets stringent international standards for quality, safety, and efficacy. The designation will facilitate procurement by public health agencies and international organizations, helping to expand access to this life-saving therapy, particularly in malaria-endemic regions.
Malaria remains a major global health challenge. In 2024, an estimated 282 million cases and 610,000 deaths were reported across 80 countries. Africa bears the…
